SunTrust Robinson Humphrey analyst Edward Nash raised the price target on Ra Pharma (NASDAQ: RARX) to $35.00 (from $28.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Ra Pharmaceuticals (RARX) Prices 8.387M Share Common Offering at $15.50/ShDecember 12, 2018 5:49 AM Ra Pharma (RARX) PT Raised to $34 at BMO CapitalDecember 10, 2018 10:21 AM Ra Pharma (RARX) PT Raised to $40 at JefferiesDecember 10, 2018 10:14 AM Ra Pharmaceuticals (RARX) Reports Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10, 2018 7:01 AM Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia GravisDecember 10, 2018 7:00 AM Ra Pharmaceuticals (RARX) Secures Development Milestone Payment Under Agreement with Merck (MRK)December 6, 2018 7:34 AM